TrialPloS one2014

Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.

Patricia Echeverría et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.